Monthly Prescribing Reference

Sucraid Single-Use Containers Approved for Congenital Sucrase-Isomaltase Deficiency

Sucraid is an oral enzyme replacement therapy of the genetically determined sucrase deficiency. The Food and Drug Administration (FDA) has approved Sucraid ® (sacrosidase) Oral Solution single-use ...
Medindia

Sucraid® (sacrosidase) Oral Solution. Free 4-Day Trial Now Available. The only FDA- approved therapy to treat CSID (Congenital Sucrase-Isomaltase Deficiency)

VERO BEACH, Fla., March 1, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid® (sacrosidase) Oral Solution has been shown to be 81% ...
KRON4 News

QOL Medical, LLC receives FDA approval of Sucraid® (sacrosidase) Oral Solution single-use containers for patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

VERO BEACH, Fla., Sept. 6, 2022 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, announced today that the United States (U.S.) Food & Drug Administration (FDA) ...
Monthly Prescribing Reference

Sucraid Supply Restored for Patients With Genetic Sucrase-Isomaltase Deficiency

The Company stated that they are now able to meet all prescription demands for Sucraid without informed consent. QOL Medical has announced that the supply of Sucraid (sacrosidase) Oral Solution has ...
Mena FN

Sucraid Global Market Report 2025: An In-Depth Study Of The Growing Market For Sucrase-Isomaltase Deficiency Treatment

LONDON, GREATER LONDON, UNITED KINGDOM, March 14, 2025 /EINPresswire / -- How Has the Sucraid Market Grown in Recent Years? The Sucraid market, which serves as a crucial enzyme replacement therapy for ...